| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CANLET.2013.07.007 |
| P8608 | Fatcat ID | release_my4tclzyvzew7mfwypo7pnpscq |
| P698 | PubMed publication ID | 23856031 |
| P5875 | ResearchGate publication ID | 249646983 |
| P2093 | author name string | Yuji Yamamoto | |
| Kazuma Takase | |||
| Masao Iwata | |||
| Kotaro Kodama | |||
| Akihiko Tsuruoka | |||
| Kiyoshi Okamoto | |||
| Naoko Hata Sugi | |||
| P2860 | cites work | The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 97-103 | |
| P577 | publication date | 2013-07-12 | |
| P1433 | published in | Cancer Letters | Q326372 |
| P1476 | title | Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models | |
| P478 | volume | 340 |
| Q52668428 | A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib. |
| Q49226937 | A perspective on multi-target drug discovery and design for complex diseases. |
| Q36716739 | A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment |
| Q92915641 | Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers |
| Q34253418 | Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models |
| Q37393234 | Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer |
| Q53520555 | Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor. |
| Q47863818 | Clinical guidance for radioiodine refractory differentiated thyroid cancer. |
| Q39442851 | Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma. |
| Q58710790 | Combined effects of Lenvatinib and iodine-131 on cell apoptosis in nasopharyngeal carcinoma through inducing endoplasmic reticulum stress |
| Q100465021 | Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma |
| Q38823954 | Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer |
| Q42680724 | Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial. |
| Q92100362 | Dexamethasone and lenvatinib inhibit migration and invasion of non-small cell lung cancer by regulating EKR/AKT and VEGF signal pathways |
| Q41992834 | Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization |
| Q38754388 | Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses |
| Q38612008 | Drug safety evaluation of lenvatinib for thyroid cancer. |
| Q34558883 | E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts |
| Q38843403 | Efficacy of lenvatinib in treating thyroid cancer. |
| Q38172608 | Emerging protein kinase inhibitors for non-small cell lung cancer |
| Q38630967 | Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer |
| Q36189141 | Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics |
| Q57809492 | Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report |
| Q52609129 | Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. |
| Q64091327 | Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges |
| Q98665205 | Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies |
| Q47104655 | In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET. |
| Q37723370 | Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes |
| Q64097520 | Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer |
| Q90299970 | Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer |
| Q90331084 | Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction |
| Q37672425 | Lenvatinib for Anaplastic Thyroid Cancer. |
| Q38754614 | Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy |
| Q89647095 | Lenvatinib in Management of Solid Tumors |
| Q54111915 | Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. |
| Q92684130 | Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial |
| Q92486987 | Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells |
| Q30249385 | Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma |
| Q64073094 | Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment |
| Q59571527 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial |
| Q64880175 | Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. |
| Q38729953 | Lenvatinib: A Review in Refractory Thyroid Cancer |
| Q26775043 | Lenvatinib: Role in thyroid cancer and other solid tumors |
| Q38385844 | Lenvatinib: first global approval |
| Q38653663 | Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches |
| Q46573222 | Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison |
| Q55617920 | Method validation studies and an inter-laboratory cross validation study of lenvatinib assay in human plasma using LC-MS/MS. |
| Q90194104 | Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice |
| Q35136424 | Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 |
| Q35434188 | Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2. |
| Q92255821 | NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells |
| Q27853306 | NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer |
| Q58784257 | Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond |
| Q96303462 | New Therapies for Advanced Thyroid Cancer |
| Q38949133 | New therapeutic perspectives in CCDC6 deficient lung cancer cells |
| Q38260495 | Novel therapies for thyroid cancer |
| Q89737237 | Peptides containing the MXXCW motif inhibit oncogenic RET kinase activity with a novel mechanism of action |
| Q36825455 | Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma |
| Q36924717 | Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer |
| Q55413273 | Prolonged duration of response in lenvatinib responders with thyroid cancer. |
| Q93202753 | Prospects of multitarget drug designing strategies by linking molecular docking and molecular dynamics to explore the protein-ligand recognition process |
| Q59136613 | RET rearrangements are actionable alterations in breast cancer |
| Q33433315 | Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis |
| Q92755252 | Second-line lenvatinib in patients with recurrent endometrial cancer |
| Q89947364 | Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib |
| Q26751274 | Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives |
| Q36467394 | Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer |
| Q47601932 | Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes |
| Q33607412 | Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus |
| Q53153700 | The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition. |
| Q38579925 | Treatment of advanced thyroid cancer: role of molecularly targeted therapies |
| Q26862841 | Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer |
| Q52587807 | Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). |
| Q41660750 | Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation. |
| Q93088927 | Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma |
| Q27023383 | Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally? |
| Q92980997 | Wound Dressings Based on Chitosan-Dialdehyde Cellulose Nanocrystals-Silver Nanoparticles: Mechanical Strength, Antibacterial Activity and Cytotoxicity |
Search more.